Cytotoxicity Enhanced Synthetic TIL Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Introduction

The field of cancer immunotherapy is rapidly advancing, with tumor-infiltrating lymphocytes (TILs) playing a pivotal role in adoptive cell transfer therapies. TILs represent a unique class of immune cells extracted directly from tumor environments, capable of recognizing and attacking tumor cells. At Creative Biolabs, our focus is on augmenting the cytotoxic potential of TILs to improve cancer treatment outcomes. Through our research and development initiatives, we've engineered synthetic TILs with enhanced tumor-killing capabilities, promising a new frontier in combating refractory and metastatic cancers.

Cytotoxicity Enhanced Synthetic TIL Development Service at Creative Biolabs

Creative Biolabs offers cutting-edge services in the development of synthetic TILs, engineered through a combination of genetic modification and advanced culture techniques. Our service is designed to amplify the natural abilities of TILs, thereby increasing their proliferative and cytotoxic responses against cancer cells. Our scientific team at Creative Biolabs employs several strategies to bolster the cytotoxic potential of synthetic TILs:

Genetic Engineering

We utilize advanced gene-editing techniques to enhance the recognition and destruction of cancer cells by TILs. This modification increases the specificity and efficiency of TILs in targeting tumor-associated antigens (TAAs).

Synthetic Immune Niche

By integrating potent co-factors in promoting T-cell activation and expansion, we create an optimal culture milieu that supports TIL expansion and functional enhancement.

Rapid Expansion Protocol

We implement an optimized rapid expansion protocol that includes feeder cells, IL-2 supplementation, and anti-CD3/CD28 antibodies to significantly increase the yield of functional TILs for therapeutic use.

Features of Our Cytotoxicity Enhanced Synthetic TIL Development

Our development service presents distinct features that set Creative Biolabs apart:

Customized Solutions: Tailored TIL expansion methods based on specific tumor profiles, ensuring personalized therapeutic strategies.
High-Throughput Capability: Efficient TIL culture systems that maximize cell yields and minimize processing time.
Superior Anti-tumor Reactivity: The integration of chemically defined membranes in the expansion process allows for improved TIL activation and survival post-infusion.

Scientific Backing

The efficacy of synthetic TILs is backed by extensive research, including key studies that highlight the enhanced proliferation and functionality of TILs when cultured with CCL21 and ICAM-1. These components not only augment TIL expansion but also empower them to overcome the suppressive tumor microenvironment, leading to effective tumor regression and improved patient outcomes.

Fig.1 Cytotoxicity of TIL when cultured with CCL21 and ICAM-1.^1,2

Frequently Asked Questions

Q1: How does the synthetic niche improve TIL functionality?

A1: The synthetic niche, such as CCL21 and ICAM-1 enhances the proliferation and cytotoxicity of TILs by mimicking the natural signals required for T-cell activation and expansion, thereby improving their tumor-targeting capabilities.

Q2: What is the turnaround time for the TIL development service?

A2: The timeline can vary depending on the complexity and scale of the project but typically ranges from several weeks to a few months, delivering high-quality, ready-to-infuse TIL products for clinical use.

Creative Biolabs continues to lead the innovation in synthetic TIL development, providing enhanced immunotherapy solutions that stand at the forefront of cancer treatment advancements. Our commitment to scientific excellence and patient-focused applications remains the cornerstone of our mission to defeat cancer.

References

Yunger, Sharon, et al. "Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1." Frontiers in Oncology 13 (2023): 1116328.
Distributed under Open Access License CC BY 4.0, without modification.